Abstract Background This exploratory sub-analysis of the EMPA-HEART CardioLink-6 trial examined whether the previously reported benefit of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin on left ventricular (LV) mass (LVM) regression differs between individuals of South Asian and non-South Asian ethnicity. Methods EMPA-HEART CardioLink-6 was a double-blind. placebo-... https://stnicksknives.shop/product-category/anodizing-service/